Dr Genevieve Steiner's research spans the early detection, prevention, and treatment of cognitive decline in older age, mild cognitive impairment, and dementia.
Dr Steiner uses neuroimaging and physiological research methods to explore the brains function and structure to discover biomarkers and test new treatment strategies for cognitive decline with a focus on herbal medicine. She is leading the worlds first clinical trial evaluating the effect of cannabidiol on cognition in people with early-stage Alzheimers disease.
Dr Steiner is rapidly rising star in the field of dementia research: she is a Young Tall Poppy Science awardee, an NHMRC-ARC Dementia Research Development Fellow, she leads the NICM Health Research Institutes Clinical Laboratory at Western Sydney University, is President of the Australasian Society for Psychophysiology, and Deputy Director of the Sydney Partnership for Health, Education, Research, and Enterprise (SPHERE) Age and Ageing Clinical Academic Group.
Dr Genevieve Steiner and Andrew dive deep into the complexity of dementia, exploring diagnosis, progression, contributing factors in its aetiology, and Genevieve’s exciting research on herbal interventions in the treatment of dementia and cognitive decline.